The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
Open accessAbstract
The administration of the immunosuppressive humanized monoclonal antibody CAMPATH 1-H, which recognizes CD52 on lymphocytes and monocytes, is associated with a first-dose cytokine-release syndrome involving TNFalpha, IFNgamma, and IL-6 clinically. In vitro models have been used to establish the cellular source and mechanism responsible for cytokine release, demonstrating that cytokine release is isotype dependent, with the rat IgG2b and human IgG1 isotype inducing the highest levels of cytokine release, which was inhibited with antibody to CD16, the low affinity Fc-receptor for IgG (FcgammaR). Cross-linking antibody opsonized CD4 T lymphocytes failed to stimulate TNFalpha release, which together with the observation that TNFalpha release by purified natural killer (NK) cells stimulated by fixed autologous CAMPATH 1-H-opsonized targets was inhibited with anti-CD16, indicates that cytokine release results from ligation of CD16 on the NK cells, rather than Fc-receptor (FcR)-dependent cross-linking of CD52 on the targeted cell. Since the hierarchy of isotypes inducing cytokine release in these cultures matches that seen clinically, we conclude that ligation of CD16 on NK cells is also responsible for cytokine release after injection of CAMPATH 1-H in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was established that TGN1412 stimulates CD4+ T-cells to undergo lymphoproliferation and release pro-inflammatory cytokines (Stebbings et al., 2007).”
From After TGN1412: Recent developments in cytokine release assays (2013) · cites this paper as Wing et al., 1996
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This mechanism of cytokine release would likely involve engagement of CD16 (FcgammaRIII) on NK cells by the Fc component of immobilized therapeutic mAbs 25 .”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. P. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,565
Self-citationOrtho Multicenter Transplant Study Group* (1985) · New England Journal of Medicine · doi:10.1056/nejm198508083130601 · Cited by 720
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
Hale, G., Clark, M., Marcus, R. E., Winter, G. P., Dyer, M. J. S., Phillips, J. M., Riechmann, L., & Waldmann, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90588-0 · Cited by 688
Self-citationHan, J. S., Thompson, P., & Beutler, B. (1990) · The Journal of Experimental Medicine · doi:10.1084/jem.172.1.391 · Cited by 508
Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells
Lanier, L. L., Yu, G., & Phillips, J. H. (1989) · Nature · doi:10.1038/342803a0 · Cited by 436
PERUSSIA, B., Starr, S. E., Abraham, S. R., Fanning, V., & Trinchieri, G. (1983) · The Journal of Immunology · doi:10.4049/jimmunol.130.5.2133 · Cited by 409
TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION WITH OKT3 MONOCLONAL ANTIBODY
Cosimi, A. B., Burton, R. C., Colvin, R. B., Goldstein, G., Delmonico, F. L., LaQuaglia, M. P., TOLKOFF-RUBIN, N. E., Rubin, R. H., Herrin, J. T., & Russell, P. S. (1981) · Transplantation · doi:10.1097/00007890-198112000-00018 · Cited by 389
Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA.
Arya, S. K., Wong‐Staal, F., & Gallo, R. C. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.133.1.273 · Cited by 387
Anegón, I., Cuturi, M. C., Trinchieri, G., & PERUSSIA, B. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.167.2.452 · Cited by 368
Dyer, M. J. S., Hale, G., Hayhoe, F. G. J., & Waldmann, H. (1989) · Blood · doi:10.1182/blood.v73.6.1431.1431 · Cited by 349
Self-citationHale, G., Xia, M., Tighe, H., Dyer, M. J. S., & Waldmann, H. (1990) · Tissue Antigens · doi:10.1111/j.1399-0039.1990.tb01767.x · Cited by 328
Self-citationIN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION
Chatenoud, L., Ferran, C. J., Legendre, C. M., Thouard, I., Merite, S., REUTER, A. M., Gevaert, Y., Kreis, H., Franchimont, P., & Bach, J. (1990) · Transplantation · doi:10.1097/00007890-199004000-00009 · Cited by 319
Humanised monoclonal antibody therapy for rheumatoid arthritis
Isaacs, J. D., Hale, G., Cobbold, S. P., Waldmann, H., Watts, R. A., Hazleman, B. L., & Keogan, M. T. (1992) · The Lancet · doi:10.1016/0140-6736(92)92294-p · Cited by 308
Self-citationTransient increase in symptoms associated with cytokine release in patients with multiple sclerosis
Moreau, T., Coles, A. J., Wing, M. G., Isaacs, J. D., Hale, G., Waldmann, H., & Compston, A. (1996) · Brain · doi:10.1093/brain/119.1.225 · Cited by 249
Self-citationBauer, J., Ganter, U., Geiger, T. M., Jacobshagen, U., Hirano, T., Matsuda, T., Kishimoto, T., Andus, T., Acs, G., & Gerok, W. (1988) · Blood · doi:10.1182/blood.v72.4.1134.1134 · Cited by 234
Monoclonal-Antibody Therapy in Systemic Vasculitis
Mathieson, P. W., Cobbold, S. P., Hale, G., Clark, M., Oliveira, D. B. G., Lockwood, C. M., & Waldmann, H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230407 · Cited by 232
Self-citationGlucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblasts
Waage, A., Slupphaug, G., & Shalaby, R. (1990) · European Journal of Immunology · doi:10.1002/eji.1830201112 · Cited by 231
Robertson, M. J., Caligiuri, M. A., Manley, T. J., Levine, H., & Ritz, J. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.10.3194 · Cited by 218
Okusawa, S., Yancey, K. B., van der Meer, J. W., Endres, S., Lonnemann, G., Hefter, K., Frank, M., Burke, J. F., Dinarello, C. A., & Gelfand, J. A. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.168.1.443 · Cited by 213
Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy
Lockwood, C. J. (1993) · The Lancet · doi:10.1016/0140-6736(93)90759-a · Cited by 203
Moreau, T., Scolding, N. J., Compston, A., Thorpe, J. W., Miller, D., MOSELEY, I. F., Hale, G., Waldmann, H., Clayton, D. G., Wing, M. G., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91339-0 · Cited by 186
Self-citationAlegre, M., Peterson, L. J., Xu, D., Sattar, H. A., Jeyarajah, D. R., Kowalkowski, K. L., Thistlethwaite, J. R., Zivin, R. A., Jolliffe, L. K., & Bluestone, J. A. (1994) · Transplantation · doi:10.1097/00007890-199457110-00001 · Cited by 171
Cytokine regulation of interleukin 6 production by human endothelial cells
Shalaby, M. R., Waage, A., & Espevik, T. (1989) · Cellular Immunology · doi:10.1016/0008-8749(89)90036-1 · Cited by 166
Regulation of the expression of IL-6 in human monocytes.
Navarro, S., Debili, N., Bernaudin, J., Vainchenker, W., & Doly, J. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.12.4339 · Cited by 162
Signal transduction events leading to T-cell lymphokine gene expression
Fraser, J. D., Straus, D. B., & Weiss, A. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90236-e · Cited by 152
Structural motifs involved in human IgG antibody effector functions
Greenwood, J., Clark, M., & Waldmann, H. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230518 · Cited by 126
Self-citationAlegre, M. L. S., Collins, A., Pulito, V. L., Brosius, R., Olson, W. C., Zivin, R. A., Knowles, R. W., Thistlethwaite, J. R., Jolliffe, L. K., & Bluestone, J. A. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.11.3461 · Cited by 116
Letourneur, O., Kennedy, I. C. S., Brini, A. T., Ortaldo, J. R., O’Shea, J. J., & Kinet, J.-P. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.8.2652 · Cited by 110
Sármay, G., Lund, J., Rozsnyay, Z., Gergely, J., & Jefferis, R. (1992) · Molecular Immunology · doi:10.1016/0161-5890(92)90200-h · Cited by 109
Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes
Rowan, W. C., Hale, G., Tite, J. P., & Brett, S. J. (1995) · International Immunology · doi:10.1093/intimm/7.1.69 · Cited by 100
Self-citationStein, M., & Gordon, S. (1991) · European Journal of Immunology · doi:10.1002/eji.1830210227 · Cited by 89
Bazzoni, F., Cassatella, M. A., Laudanna, C., & Rossi, F. (1991) · Journal of Leukocyte Biology · doi:10.1002/jlb.50.3.223 · Cited by 82
Molecular definition of interaction sites on human IgG for Fc receptors (huFcγR)
Jefferis, R., Lund, J., & Pound, J. D. (1990) · Molecular Immunology · doi:10.1016/0161-5890(90)90027-w · Cited by 61
Melero, I., Balboa, M. A., Aionso, J. L., Yagüe, E., Pivel, J. P., Sánchez‐Madrid, F., & López‐Botet, M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230819 · Cited by 47
In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.
Parlevliet, K. J., ten Berge, I. J. M., Yong, S. L., Surachno, J. S., Wilmink, J. M., & Schellekens, P. T. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117262 · Cited by 47
Friend, P. J., Rebello, P., Oliveira, D. B. G., Manna, V. K., Cobbold, S. P., Hale, G., Jamieson, N. V., Jamieson, I. R., Calne, R. Y., & Harris, D. T. (1995) · PubMed · Cited by 38
Self-citationWing, M. G., Waldmann, H., Isaacs, J. D., Compston, D. A. S., & Hale, G. (1995) · PubMed · Cited by 37
Self-citationNishimura, T., & Itoh, T. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181231 · Cited by 31
The use of polymyxin B and C3H/HeJ mouse spleen cells as criteria for endotoxin contamination
Morrison, D. C., & Curry, B. J. (1979) · Journal of Immunological Methods · doi:10.1016/0022-1759(79)90241-2 · Cited by 20
Hirsch, R., Bluestone, J. A., Bare, C. V., & Gress, R. E. (1991) · PubMed · Cited by 18
Butler, T., & Möller, G. (1977) · Infection and Immunity · doi:10.1128/iai.18.2.400-404.1977 · Cited by 13
Wing, M. G., Montgomery, A. M. P., HARLEY, C., & Lachmann, P. J. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb05428.x · Cited by 11
Self-citationC3a and C3a-desARG induce release of IL-6 and TNF-a from human monocytes
Schermuck, S. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90359-j · Cited by 2
Cited by
Sorted by citations
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Shimabukuro‐Vornhagen, A., Gödel, P., Subklewe, M. S., Stemmler, H., Schlößer, H., Schlaak, M. S., Kochanek, M., Böll, B., & von Bergwelt‐Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,712
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,185
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy — Oncolytics · doi:10.1038/mto.2016.11 · Cited by 911
Metadata
- Authors
- Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A.
- Affiliations
- Medical Research Council (GB)
- University of Cambridge (GB)
- University of Oxford (GB)
- Venue
- Journal of Clinical Investigation
- Published
- 1996-12-15
- Volume
- 98
- Issue
- 12
- Pages
- 2819-2826
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC507749
- OpenAlex
- W2069219892
- Cited by
- 257
- References
- 43
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 8 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 12 · 2019: 15 · 2018: 11 · 2017: 11 · 2016: 11 · 2015: 7 · 2014: 8 · 2013: 12 · 2012: 8
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Medical Research Council
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, CD52, natural killer cells, CD16, Fc gamma receptor I, LFA-1, CD11a/CD18, antibody isotypes, TNF-α, interferon-gamma, interleukin-6
- MeSH terms
- Alemtuzumab, Antibodies, Monoclonal, Antibodies, Neoplasm, Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin G, Immunoglobulin M, Interferon-gamma, Killer Cells, Natural, Leukocytes, Tumor Necrosis Factor-alpha, CD4-Positive T-Lymphocytes, Interleukin-6, Cytokines, Receptors, IgG, CD11 Antigens, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
